July 18, 2007 — Within the next year, clinicians can expect a new and improved Unified Parkinson's Disease Rating Scale (UPDRS), the current gold standard and most widely used clinical assessment tool ...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...
A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a ...
Harrison et al. have attempted to validate Part II of the Unified Parkinson's Disease Rating Scale (UPDRS II) as a medication-independent measure of disease progression. The authors collected ...
Researchers sought to determine the relationship between neuroimaging markers and other clinical characteristics with mild parkinsonian signs in older adults. Lower gray matter integrity found at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results